These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 17433855

  • 1. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y.
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [Abstract] [Full Text] [Related]

  • 2. Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    von der Maase H.
    Eur Urol; 2007 Oct; 52(4):1122. PubMed ID: 17433856
    [No Abstract] [Full Text] [Related]

  • 3. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ, Meyers FJ, Houston J, Lauder I.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    Johannsen M, Sachs M, Roigas J, Hinke A, Staack A, Loening SA, Schnorr D, Wille AH.
    Eur Urol; 2005 Aug; 48(2):246-51. PubMed ID: 15963636
    [Abstract] [Full Text] [Related]

  • 6. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED.
    Cancer; 2005 Oct 15; 104(8):1627-32. PubMed ID: 16138364
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    Soga N, Onishi T, Arima K, Sugimura Y.
    Int J Urol; 2007 Sep 15; 14(9):828-32. PubMed ID: 17760750
    [Abstract] [Full Text] [Related]

  • 9. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
    Mulatero C, McClaren BR, Mason M, Oliver RT, Gallagher CJ.
    Br J Cancer; 2000 Dec 15; 83(12):1612-6. PubMed ID: 11104554
    [Abstract] [Full Text] [Related]

  • 10. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC, Hsu CH, Huang CY, Cheng AL, Vogelzang NJ, Pu YS.
    J Urol; 2007 Jan 15; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [Abstract] [Full Text] [Related]

  • 11. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S, Perry MC, La Rocca RV, Rinaldi D, Gable PS, Tester WJ, Belani CP.
    Cancer; 2008 Aug 01; 113(3):542-6. PubMed ID: 18512224
    [Abstract] [Full Text] [Related]

  • 12. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
    Hoekstra AV, Hurteau JA, Kirschner CV, Rodriguez GC.
    Gynecol Oncol; 2009 Dec 01; 115(3):377-81. PubMed ID: 19800107
    [Abstract] [Full Text] [Related]

  • 13. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP, Ramalingam S, Perry MC, LaRocca RV, Rinaldi D, Gable PS, Tester WJ.
    J Clin Oncol; 2008 Jan 20; 26(3):468-73. PubMed ID: 18202422
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD, Spigel DR, Litchy S, Greco FA.
    J Clin Oncol; 2006 Aug 01; 24(22):3548-54. PubMed ID: 16877720
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical study of combination chemotherapy of methotrexate, epirubicin and nedaplatin (MEN) in patients with advanced urothelial carcinoma].
    Hattori Y, Takizawa A, Kishida T, Kakizoe M, Fujikawa N, Teranishi J, Kondo K, Saito K, Noguchi K, Nakaigawa N, Kubota Y.
    Gan To Kagaku Ryoho; 2007 May 01; 34(5):739-43. PubMed ID: 17496448
    [Abstract] [Full Text] [Related]

  • 19. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, Dimopoulos MA, Hellenic Co-operative Oncology Group.
    Gynecol Oncol; 2008 Jul 01; 110(1):87-92. PubMed ID: 18455782
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.